<DOC>
	<DOCNO>NCT00754559</DOCNO>
	<brief_summary>This single arm study ass effectiveness tocilizumab combination traditional DMARDs regard clinical improvement disease activity ( achievement LDAS ) 24 week ' treatment patient active rheumatoid arthritis ( RA ) inadequate response current traditional DMARD and/or anti-TNF therapy . Patients receive tocilizumab 8mg/kg iv every 4 week , addition ongoing DMARDs stable pre-entry dose prescribed physician , total 6 infusion regular treatment period 6 infusion optional extension phase . The anticipated time study treatment 6 12 month , target sample size &lt; 500 individual .</brief_summary>
	<brief_title>A Study Assess Efficacy With Respect Clinical Improvement Disease Activity Safety Tocilizumab Patients Wtih Active Rheumatoid Arthritis .</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; rheumatoid arthritis &gt; =6 month duration diagnose accord revised 1987 ACR criterion ; DAS28 &gt; 3.2 ; At screen either ESR &gt; =28 mm/h CRP &gt; =1 mg/dL ; Having receive permitted DMARDs , 1 ; current DMARD therapy must stable dose least 8 week prior baseline . major surgery ( include joint surgery ) within 8 week prior screen plan major surgery within 6 month follow screening ; functional class IV identify ACR classification functional status RA ; rheumatoid autoimmune disease RA ; prior history current inflammatory joint disease RA .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>